OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 8,779 GILD derivative securities | OQRO

Home
Insider trades
Gilead Sciences
CEO exercised or converted 8,779 GILD derivative securities

Insider trades

Insider trade

CEO exercised or converted 8,779 GILD derivative securities

Traded Jun 10, 2026 · Filed Jun 11, 2026

GILGilead SciencesGILD

8,779
Shares

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 10, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 11, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001638643-26-000024

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Jun 11, 2026, 10:29 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Daniel Patrick O'day

Relationship

Director, Officer

Officer title

Chairman & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jun 10, 2026

Transaction code

Shares / units

8,779

Acquired / disposed

Acquired (A)

Shares owned after

626,346

Ownership form

Direct

Amendment

Footnotes from the filing

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Around the same time

Daniel Patrick O'day (Chairman & CEO) sold ~$1.5M of Gilead Sciences

Scheduled in advanceFiled 3mo ago

Daniel Patrick O'day (Chairman & CEO) sold ~$394K of Gilead Sciences

Scheduled in advanceFiled 3mo ago

Jared MoskowitzDemocrat, Representative, FL district 23D · FL-23

Disclosed 4mo ago

Bought

$1,001–$15,000

Traded May 6 · disclosed 44 days laterDependent child

2 different filers disclosed GILD within 90 days.

More Official record